섬유낭종 진단 및 치료 시장 규모 : 유형별, 최종 사용자별 - 지역별 전망, 경쟁 전략 및 부문 예측(-2033년)

Fibrocystic Breasts Diagnostics Treatment Market Size- By Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

US $ 4,250 ￦ 6,149,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인용 시에는 출처를 명시해 주시기 바랍니다

US $ 5,650 ￦ 8,174,000

PDF (Group License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 인용 시에는 출처를 명시해 주시기 바랍니다.

US $ 7,450 ￦ 10,779,000

PDF (Company License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 인용 시에는 출처를 명시해 주시기 바랍니다.

한글목차

세계의 섬유낭종 진단 및 치료 시장 규모는 2033년까지 8.11%의 연평균 복합 성장률(CAGR)로 추이할 전망이며, 311억 7,000만 달러 규모에 달할 것으로 예측됩니다.

세계의 섬유낭종 진단 및 치료 시장은 COVID-19의 유행에 의해 큰 영향을 받고 있습니다. COVID-19 환자를 선호하고 감염의 위험을 낮추기 위해 유행 피크시에는 긴급하지 않은 많은 치료가 중단되거나 지연되었습니다. 그 결과, 섬유낭종 질환 환자는 진단 및 치료 과정이 지연되어 합병증을 유발하거나 질병이 진행될 수 있습니다.

본 보고서에서는 세계의 섬유낭종 진단 및 치료 시장을 조사했으며 시장 개요, 시장영향인자 및 시장기회 분석, 시장 규모 추이 및 예측, 각종 구분, 지역 및 주요 국가별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

• 성장 촉진요인 및 억제요인, 기회, 과제 분석
• 시장에 대한 COVID-19의 영향

제5장 시장 변수 및 전망

• SWOT 분석
• PESTEL 분석
• Porter's Five Forces 분석
• 히트맵 분석

제6장 경쟁 구도

• 제조 거점의 분포, 판매 에리어 및 제품 유형
• M&A, 제휴, 제품 발매 및 협력

제7장 세계의 섬유낭종 진단 및 치료 시장 : 유형별

• 세계 시장 규모 : 점유율 및 예측
• 진단
• 유방 조영
• 유방 생검
• 치료
• 의약품
• 아세트아미노펜
• 비스테로이드성 항염증제
• 천자 흡인법
• 외과적 절제
• 경구 피임약

제8장 세계의 섬유낭종 진단 및 치료 시장 : 최종 사용자별

• 세계 시장 규모 : 점유율 및 예측
• 병원
• 클리닉
• 진단센터
• 전문 클리닉 및 재활센터
• 연구기관
• 기타

제9장 세계의 섬유낭종 진단 및 치료 시장 예측

• 시장 규모 및 시장 점유율

제10장 세계의 섬유낭종 진단 및 치료 시장 : 지역별

• 시장 규모, 시장 점유율의 추이 및 예측
• 아시아태평양
• 유럽
• 중동 및 아프리카
• 북미
• 라틴아메리카

제11장 기업 프로파일

• Argon Medical Devices
• Becton, Dickinson and Company
• Bayer AG
• Boston Scientific Corp.
• Devicor Medical Products Inc.
• Johnson & Johnson Pvt. Ltd.
• Merck
• Sanofi
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries Ltd.
• 기타

제12장 결론

제13장 약어 일람

제14장 참고 링크

AJY

영문 목차

영문목차

Fibrocystic Breasts Diagnostics Treatment Market Introduction and Overview

According to SPER market research, 'Fibrocystic Breasts Diagnostics Treatment Market Size- By Types, By End-Users - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Fibrocystic Breasts Diagnostics Treatment Market is predicted to reach USD 31.17 billion by 2033 with a CAGR of 8.11%.

Breasts feeling lumpy are a symptom of fibrocystic breast disease, a non-cancerous illness also called fibrocystic change or fibrocystic breasts. The breast lumps are caused by fibrocystic changes. These lumps develop from a concentration of fibrous tissue in one area of the breast. Changes in breast tissue brought on by fluctuations in hormone levels produced by the ovaries are the cause of fibrocystic breasts.

The worldwide market for fibrocystic breast diagnosis and therapy has been greatly influenced by the COVID-19 epidemic. Many non-urgent medical treatments were canceled or postponed during the peak of the pandemic in order to prioritize COVID-19 patients and lower the risk of transmission. As a result, people who have fibrocystic breast disorders might have had delays in their diagnosis and course of treatment, which could have resulted in complications or the advancement of their illness.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Types, By End Users

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Argon Medical Devices, Becton,Dickson and Company, Bayer AG, Boston Scientific Corp, Devicor Medical Products Inc., Johnson & Johnson Pvt. Ltd., Merck, Sanofi, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd.

Global Fibrocystic Breasts Diagnostics Treatment Market Segmentation:

By Types: Based on the Types, Global Fibrocystic Breasts Diagnostics Treatment Market is segmented as; Diagnosis, Mammogram, Breast Biopsy, Treatment, Medications, Acetaminophen. Non-steroidal anti-inflammatory Drugs, Fine-Needle Aspiration, Surgical Excision, Oral Contraceptive

By End-Users: Based on the End-Users, Global Fibrocystic Breasts Diagnostics Treatment Market is segmented as; Hospitals, Clinics, Diagnostic Centers, Speciality Clinics and Rehab Centers, Research Institutes, Others.)

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Table of Contents

1. Introduction

• 1.1. Scope of the report
• 1.2. Market segment analysis

2. Research Methodology

• 2.1. Research data source
  • 2.1.1. Secondary Data
  • 2.1.2. Primary Data
  • 2.1.3. SPER's internal database
  • 2.1.4. Premium insight from KOL's
• 2.2. Market size estimation
  • 2.2.1. Top-down and Bottom-up approach
• 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

• 4.1. Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Opportunities
  • 4.1.4. Challenges
• 4.2. COVID-19 Impacts of the Global Fibrocystic Breasts Diagnostics Treatment Market.

5. Market variable and outlook

• 5.1. SWOT Analysis
  • 5.1.1. Strengths
  • 5.1.2. Weaknesses
  • 5.1.3. Opportunities
  • 5.1.4. Threats
• 5.2. PESTEL Analysis
  • 5.2.1. Political Landscape
  • 5.2.2. Economic Landscape
  • 5.2.3. Social Landscape
  • 5.2.4. Technological Landscape
  • 5.2.5. Environmental Landscape
  • 5.2.6. Legal Landscape
• 5.3. PORTER's Five Forces
  • 5.3.1. Bargaining power of suppliers
  • 5.3.2. Bargaining power of buyers
  • 5.3.3. Threat of Substitute
  • 5.3.4. Threat of new entrant
  • 5.3.5. Competitive rivalry
• 5.4. Heat Map Analysis

6. Competitive Landscape

• 6.1. Global Fibrocystic Breasts Diagnostics Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
• 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Fibrocystic Breasts Diagnostics Treatment Market

7. Global Fibrocystic Breasts Diagnostics Treatment Market, By Type (USD Million) 2020-2033

• 7.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By Type, 2020-2026
• 7.2. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By Type, 2027-2033
• 7.3. Diagnosis
• 7.4. Mammogram
• 7.5. Breast Biopsy
• 7.6. Treatment
• 7.7. Medications
• 7.8. Acetaminophen
• 7.9. Non-steroidal Inflammatory Drugs
• 7.10. Fine-needle Aspirations
• 7.11. Surgical Excision
• 7.12. Oral Contraceptives

8. Global Fibrocystic Breasts Diagnostics Treatment Market, By End-Users (USD Million)2020-2033

• 8.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By End Users, 2020-2026
• 8.2. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By End Users, 2027-2033
• 8.3. Hospitals
• 8.4. Clinics
• 8.5. Diagnostic Centers
• 8.6. Speciality Clinics and Rehab Centers
• 8.7. Research Institutes
• 8.8. Others

9. Global Fibrocystic Breasts Diagnostics Treatment Market Forecast, 2020-2033 (USD Million)

• 9.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size and Market Share

10. Global Fibrocystic Breasts Diagnostics Treatment Market, By Region, 2020-2033 (USD Million)

• 10.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size and Market Share By Region (2020-2026)
• 10.2. Global Fibrocystic Breasts Diagnostics Treatment Market Size and Market Share By Region (2027-2033)
• 10.3. Asia-Pacific
  • 10.3.1. Australia
  • 10.3.2. China
  • 10.3.3. India
  • 10.3.4. Japan
  • 10.3.5. South Korea
  • 10.3.6. Rest of Asia-Pacific
• 10.4. Europe
  • 10.4.1. France
  • 10.4.2. Germany
  • 10.4.3. Italy
  • 10.4.4. Spain
  • 10.4.5. United Kingdom
  • 10.4.6. Rest of Europe
• 10.5. Middle East and Africa
  • 10.5.1. Kingdom of Saudi Arabia
  • 10.5.2. United Arab Emirates
  • 10.5.3. Qatar
  • 10.5.4. South Africa
  • 10.5.5. Egypt
  • 10.5.6. Morocco
  • 10.5.7. Nigeria
  • 10.5.8. Rest of Middle East & Africa
• 10.6. North America
  • 10.6.1. Canada
  • 10.6.2. Mexico
  • 10.6.3. United States
• 10.7. Latin America
  • 10.7.1. Argentina
  • 10.7.2. Brazil
  • 10.7.3. Rest of Latin America

11. Company Profile

• 11.1. Argon Medical Devices
  • 11.1.1. Company details
  • 11.1.2. Financial outlook
  • 11.1.3. Product summary
  • 11.1.4. Recent developments
• 11.2. Becton, Dickinson and Company
  • 11.2.1. Company details
  • 11.2.2. Financial outlook
  • 11.2.3. Product summary
  • 11.2.4. Recent developments
• 11.3. Bayer AG
  • 11.3.1. Company details
  • 11.3.2. Financial outlook
  • 11.3.3. Product summary
  • 11.3.4. Recent developments
• 11.4. Boston Scientific Corp.
  • 11.4.1. Company details
  • 11.4.2. Financial outlook
  • 11.4.3. Product summary
  • 11.4.4. Recent developments
• 11.5. Devicor Medical Products Inc.
  • 11.5.1. Company details
  • 11.5.2. Financial outlook
  • 11.5.3. Product summary
  • 11.5.4. Recent developments
• 11.6. Johnson & Johnson Pvt. Ltd.
  • 11.6.1. Company details
  • 11.6.2. Financial outlook
  • 11.6.3. Product summary
  • 11.6.4. Recent developments
• 11.7. Merck
  • 11.7.1. Company details
  • 11.7.2. Financial outlook
  • 11.7.3. Product summary
  • 11.7.4. Recent developments
• 11.8. Sanofi
  • 11.8.1. Company details
  • 11.8.2. Financial outlook
  • 11.8.3. Product summary
  • 11.8.4. Recent developments
• 11.9. Sun Pharmaceutical Industries
  • 11.9.1. Company details
  • 11.9.2. Financial outlook
  • 11.9.3. Product summary
  • 11.9.4. Recent developments
• 11.10. Teva Pharmaceutical Industries Ltd.
  • 11.10.1. Company details
  • 11.10.2. Financial outlook
  • 11.10.3. Product summary
  • 11.10.4. Recent developments
• 11.11. Others

12. Conclusion

13. List of Abbreviations

14. Reference Links

관련자료